Assessment of Bone Morphogentic protein receptor 2 Level in Pulmonary Arterial Hypertension Disease
*Corresponding Author E-mail: Arshad.firstname.lastname@example.org
In the current study, Fifty six patients of Pulmonary arterial hypertension were admitted from Echocardiography unit and Najaf Cardiac Centre in Al-Sadder Teaching City in Al-Najaf province/Iraq during September 2016 to February 2017, divided into seven groups: -First group according to gender (Male= 34, Female = 22) Second group according to the type of disease, primary included 20 patients and secondary 36 group, Third group according to Smoking included smokers 26 subjects and nonsmokers patients group included 30 subjects, Fourth group according to the type of secondary pulmonary hypertension (Vulvular 24, Chronic Obstructive Pulmonary Disease 18 and Congenital 14), fifth group according to ages (30–39 year =12, 40–49 year = 12, 50–59 year= 12, 60–69 year = 20), six group according to Grades ([Mild = 18, moderate = 18, severe; 20). The control group was composed of thirty healthy subject. The results of current study indicated, there were statistically significant decrease (p<0.05) in serum levels of Bone morphogenetic protein receptor 2 in patients of PAH in compared with healthy group. Also the results revealed a significant decrease (p<0.05) in BMPR2 in Females in compared with Males, Primary PAH than Secondary, Nonsmokers in compared with Smoker. And Chronic Obstructive Pulmonary Disease and Congenital in compared with Vulvular, Normal weight in compared with overweight and obese, 30–39 years in compared with other aged groups and in severe grades than Mild and Moderate.
The current results concluded that BMPR2 is a marker for detection and diagnosis of Pulmonary arterial hypertension.
Pulmonary arterial hypertension, BMPR2, Secondary AH.